{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:53:49Z","timestamp":1781855629771,"version":"3.54.5"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic bone diseases (MBDs) are a group of conditions characterized by imbalanced bone remodeling, including osteoporosis, osteomalacia, and rickets. In recent years, drug-induced secondary MBDs have emerged as a major clinical concern. However, systematic drug risk assessment studies based on large-scale real-world data remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS, 2004\u20132024) and VigiAccess, four complementary disproportionality algorithms (reporting odds ratio, ROR; proportional reporting ratio, PRR; Bayesian confidence propagation neural network, BCPNN; multi-item gamma Poisson shrinker, MGPS) were used to screen drug-event signals. The signals were stratified by gender and age type, and their temporal distribution characteristics were characterized using the Weibull model. Finally, the causal plausibility was assessed using the updated Bradford Hill framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 55,783 adverse event reports were included, and 33 drugs showed consistent positive signals in both the FAERS and VigiAccess databases. Major signal drugs included bisphosphonates (e.g., alendronic acid, zoledronic acid), antiviral drugs (e.g., tenofovir disoproxil fumarate, emtricitabine\/tenofovir combination), proton pump inhibitors (e.g., esomeprazole), and endocrine antineoplastic drugs (e.g., anastrozole). Within the Anatomical Therapeutic Chemical (ATC) classification, signals were primarily concentrated in anti-infectives (category J), antineoplastic and immunomodulatory drugs (category L), and musculoskeletal drugs (category M).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study systematically identified robust pharmacovigilance signals and disproportionality-based associations between multiple drug classes and metabolic bone disorders through an integrated analysis of the FAERS and VigiAccess databases, providing high-confidence real-world evidence for pharmacovigilance signal detection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1766498","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:26:56Z","timestamp":1781854016000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world pharmacovigilance of drug-related bone metabolism disorders: integrating FAERS and VigiAccess with a Bradford Hill-based causal plausibility assessment"],"prefix":"10.3389","volume":"17","author":[{"given":"Pei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Artificial Joint Revision, Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital)","place":["Zhengzhou, Henan, China"]},{"name":"Henan Provincial Engineering Research Center for Traditional Chinese Medicine Prevention and Treatment of Bone Tumors","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital South Campus","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Artificial Joint Revision, Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital)","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Artificial Joint Revision, Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital)","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Artificial Joint Revision, Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital)","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Artificial Joint Revision, Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital)","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1210\/er.2018-00001","article-title":"Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management","volume":"40","author":"Black","year":"2019","journal-title":"Endocr. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/BOR.0000000000000934","article-title":"Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist","volume":"35","author":"Chakrabarti","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2023.03.002","article-title":"Pathogenic mechanisms of glucocorticoid-induced osteoporosis","volume":"70","author":"Chen","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US food and drug administration adverse event reporting system, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American gastroenterological association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s40120-025-00805-y","article-title":"Antiseizure medications and bone health","volume":"14","author":"Gaete","year":"2025","journal-title":"Neurol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5694\/mja2.50280","article-title":"Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary","volume":"211","author":"Grossmann","year":"2019","journal-title":"Med. J. Aust."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100694","DOI":"10.1016\/j.jbo.2025.100694","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: an updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG","volume":"53","author":"Hadji","year":"2025","journal-title":"J. Bone Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e10506","DOI":"10.1002\/jbm4.10506","article-title":"Impact of tenofovir disoproxil-induced Fanconi syndrome on bone material quality: a case report","volume":"5","author":"Hadzimuratovic","year":"2021","journal-title":"JBMR Plus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00002018-200730020-00004","article-title":"Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions","volume":"30","author":"Hauben","year":"2007","journal-title":"Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S2213-8587(25)00251-7","article-title":"Glucocorticoid-induced osteoporosis: novel concepts and clinical implications","volume":"13","author":"Hofbauer","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1530\/EDM-22-0259","article-title":"Tenofovir-induced hypophosphatemic osteomalacia: how do bone mineral density, trabecular bone score and proximal hip geometry change with treatment?","volume":"2023","author":"Joseph","year":"2023","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"Leroy","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"10733","DOI":"10.3390\/ijms231810733","article-title":"Proton pump inhibitors and bone health: an update narrative review","volume":"23","author":"Lespessailles","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10067-014-2627-x","article-title":"Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients","volume":"35","author":"Mateo","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s10067-025-07360-9","article-title":"Safety of janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022","volume":"44","author":"Mikaeili","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1111\/epi.17803","article-title":"Effect of antiseizure medications on bone health","volume":"64","author":"Mikati","year":"2023","journal-title":"Epilepsia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae146","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue society","volume":"191","author":"Paccou","year":"2024","journal-title":"Eur. J. Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/cid\/ciae288","article-title":"Tenofovir Alafenamide versus Tenofovir disoproxil fumarate for preventing vertical transmission in chronic hepatitis B mothers: a systematic review and meta-analysis","volume":"79","author":"Pan","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. glucocorticoid-induced osteoporosis intervention study group","volume":"339","author":"Saag","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/acr2.11415","article-title":"Clinical images: tenofovir-induced Fanconi syndrome: an uncommon cause of hypophosphatemic osteomalacia","volume":"4","author":"Sahoo","year":"2022","journal-title":"ACR Open Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"606","DOI":"10.4103\/0253-7613.190766","article-title":"Promoting public access to VigiBase","volume":"48","author":"Shankar","year":"2016","journal-title":"Indian J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-med-050124-040555","article-title":"Recent advances in osteoporosis therapeutics","volume":"77","author":"S\u00f8lling","year":"2025","journal-title":"Annu. Rev. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10654-021-00798-6","article-title":"Strength in causality: discerning causal mechanisms in the sufficient cause model","volume":"36","author":"Suzuki","year":"2021","journal-title":"Eur. J. Epidemiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.eprac.2021.02.001","article-title":"American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal Osteoporosis-2020 update","volume":"27","author":"Watts","year":"2021","journal-title":"Endocr. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1218206","DOI":"10.3389\/fonc.2023.1218206","article-title":"The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy","volume":"13","author":"Xu","year":"2023","journal-title":"Front. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"801199","DOI":"10.3389\/fonc.2021.801199","article-title":"Cutaneous toxicity associated with enfortumab vedotin: a real-word study leveraging U.S. food and drug administration adverse event reporting system","volume":"11","author":"Yang","year":"2022","journal-title":"Front. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijid.2022.09.021","article-title":"Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"124","author":"Yang","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1639714","DOI":"10.3389\/fphar.2025.1639714","article-title":"Effects of the efficacy of the Yi Shen Tiao Gan formula on aromatase inhibitor associated musculoskeletal syndrome: a randomized controlled trial","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1007\/s11096-025-01969-1","article-title":"Pharmacovigilance analysis of metabolic and nutritional adverse reactions associated with entecavir and tenofovir using the FDA adverse event reporting system database","volume":"47","author":"Zhu","year":"2025","journal-title":"Int. J. Clin. Pharm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1766498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:26:57Z","timestamp":1781854017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1766498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1766498"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1766498","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1766498"}}